inhaled interferon - versus control - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 0.16 [0.01, 3.31]< 10%1 study (1/-)87.9 %some concernnot evaluable moderatecrucial-
clinical deterioration 0.50 [0.18, 1.38]< 10%1 study (1/-)90.9 %some concernnot evaluable moderateimportant-
clinical improvement 2.32 [1.07, 5.04]> 10%1 study (1/-)98.3 %some concernnot evaluable moderateimportant-
clinical improvement (28-day) 3.15 [1.39, 7.14]> 10%1 study (1/-)99.7 %some concernnot evaluable moderateimportant-
death or ventilation 0.38 [0.09, 1.63]< 10%1 study (1/-)90.3 %some concernnot evaluable moderateimportant-
hospital discharge 1.63 [0.61, 4.35]> 10%1 study (1/-)83.5 %some concernnot evaluable moderateimportant-
recovery 2.19 [1.03, 4.67]> 10%1 study (1/-)97.9 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.